News & Updates

Menopause linked to bladder woes

26 Jul 2024

Overactive bladder (OAB) is common among women undergoing menopause, especially among those at late menopausal stage and who have other menopausal symptoms, as reported in a cross-sectional study.

Menopause linked to bladder woes

26 Jul 2024

Original New Drug Application Approvals by US FDA (16-30 June 2024)

15 Jul 2024

New drug applications approved by US FDA as of 16-30 June 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-30 June 2024)

15 Jul 2024

Alpha-blockers hold therapeutic potential against dementia with Lewy bodies

10 Jul 2024 by

The use of the alpha-1 adrenergic receptor antagonists (alpha-blockers) terazosin, doxazosin, and alfuzosin—medications for benign prostate hyperplasia (BPH)—may help reduce the incidence of dementia with Lewy bodies (DLB) in men, as suggested in a study.

Alpha-blockers hold therapeutic potential against dementia with Lewy bodies

10 Jul 2024

Nadofaragene firadenovec promotes bladder preservation in BCG-unresponsive NMIBC

05 Jul 2024 by

Nadofaragene firadenovec-vncg helps preserve the bladder in patients with bacillus Calmette-Guérin (BCG)-unresponsive nonmuscle-invasive bladder cancer (NMIBC) at 5 years, with an acceptable safety profile, as shown in a phase III trial.

Nadofaragene firadenovec promotes bladder preservation in BCG-unresponsive NMIBC

05 Jul 2024

Bladder cancer survivors who do not smoke enjoy better life quality

04 Jul 2024

Among patients with bladder cancer (BC), those who do not smoke appear to have better longitudinal health-related quality of life (HRQoL) measures, particularly in the domains of physical function, emotional function, and fatigue, according to a recent study.

Bladder cancer survivors who do not smoke enjoy better life quality

04 Jul 2024

Bowel resection, bypass linked to increased risk of repeat stone surgery

04 Jul 2024

Among people who have undergone stone surgery, those with a history of bowel resection and bypass appear to be at increased risk of repeat stone surgery, according to a study.

Bowel resection, bypass linked to increased risk of repeat stone surgery

04 Jul 2024

Neoadjuvant avelumab plus cisplatin-based chemo confers high OS, EFS rates in MIUC

03 Jul 2024 by

The combination of avelumab and cisplatin-based chemotherapy as neoadjuvant therapy for MIUC yields high OS and EFS rates at both 1 and 3 years, according to the survival data from the dual-cohort, phase II AURA trial presented at ASCO 2024

Neoadjuvant avelumab plus cisplatin-based chemo confers high OS, EFS rates in MIUC

03 Jul 2024

Intense exercise safe for men with metastatic prostate cancer

13 Jun 2024 by

Patients with metastatic prostate cancer can safely engage in intense exercise training to improve survival outcomes, suggests a study presented at AACR 2024.

Intense exercise safe for men with metastatic prostate cancer

13 Jun 2024

Optimizing first-and subsequent-line therapy for advanced RCC

13 Jun 2024 by

The treatment landscape of metastatic renal cell carcinoma (mRCC) has undergone a major transformation in the past two decades, with interleukin-2 and interferon-α being replaced with anti-angiogenic tyrosine kinase inhibitors (TKIs), inhibitors of mammalian target of rapamycin (mTOR) and immune checkpoint inhibitors (ICIs). At an Eisai-sponsored symposium organized by the Hong Kong Society of Uro-Oncology during Uro-Oncology Asia 2024, Professor Sun-Young Rha of the Yonsei University College of Medicine in Seoul, South Korea, discussed the importance of optimizing first-line treatment and subsequent strategies for patients with advanced RCC. Rha also reviewed clinical evidence on regimens containing lenvatinib (Lenvima^®, Eisai), an oral TKI against VEGF receptor, which have been shown to improve outcomes in first and subsequent lines of therapy.

Optimizing first-and subsequent-line therapy for advanced RCC

13 Jun 2024

Oral tacrolimus benefits haemodialysis patients with uraemic pruritus

11 Jun 2024 by

A study from Iran presented at ERA 2024 demonstrated the potential of oral tacrolimus to deliver an antipruritic effect in haemodialysis patients with uraemic pruritus.

Oral tacrolimus benefits haemodialysis patients with uraemic pruritus

11 Jun 2024

News & Updates

Filter by Specialty:

Specialty:

Menopause linked to bladder woes

Menopause linked to bladder woes

Original New Drug Application Approvals by US FDA (16-30 June 2024)

Original New Drug Application Approvals by US FDA (16-30 June 2024)

Alpha-blockers hold therapeutic potential against dementia with Lewy bodies

Alpha-blockers hold therapeutic potential against dementia with Lewy bodies

Nadofaragene firadenovec promotes bladder preservation in BCG-unresponsive NMIBC

Nadofaragene firadenovec promotes bladder preservation in BCG-unresponsive NMIBC

Bladder cancer survivors who do not smoke enjoy better life quality

Bladder cancer survivors who do not smoke enjoy better life quality

Bowel resection, bypass linked to increased risk of repeat stone surgery

Bowel resection, bypass linked to increased risk of repeat stone surgery

Neoadjuvant avelumab plus cisplatin-based chemo confers high OS, EFS rates in MIUC

Neoadjuvant avelumab plus cisplatin-based chemo confers high OS, EFS rates in MIUC

Intense exercise safe for men with metastatic prostate cancer

Intense exercise safe for men with metastatic prostate cancer

Optimizing first-and subsequent-line therapy for advanced RCC

Optimizing first-and subsequent-line therapy for advanced RCC

Oral tacrolimus benefits haemodialysis patients with uraemic pruritus

Oral tacrolimus benefits haemodialysis patients with uraemic pruritus